Published in J Clin Oncol on August 01, 2000
Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer | NCT01856322
Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med (2012) 10.93
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol (2011) 5.39
Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg (2004) 5.10
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet (2011) 4.36
Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol (2010) 4.30
Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg (2004) 3.72
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer (2006) 3.26
Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg (2006) 3.05
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol (2015) 2.70
Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62
Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol (2012) 2.59
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol (2009) 2.50
High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol (2011) 2.28
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. World J Surg (2014) 2.02
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer (2011) 1.90
Zoster sine herpete: virologic verification by detection of anti-VZV IgG antibody in CSF. Neurology (2011) 1.85
A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther (2013) 1.80
Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res (2007) 1.66
Management of advanced colorectal cancer: state of the art. Br J Cancer (2006) 1.62
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer (2005) 1.61
Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut (2003) 1.61
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer (2002) 1.61
Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology (2011) 1.58
FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest (2008) 1.56
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst (2014) 1.56
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer (2008) 1.55
Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases. World J Surg (2010) 1.52
Preoperative chemotherapy and the outcome of liver resection for colorectal metastases. World J Surg (2007) 1.52
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer (2012) 1.50
Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy. J Oncol Pract (2012) 1.50
Calnexin, an ER-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer. J Transl Med (2016) 1.44
Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res (2009) 1.43
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer (2004) 1.40
Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer (2013) 1.38
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer (2013) 1.37
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol (2010) 1.36
Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer (2006) 1.35
Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol (2010) 1.31
Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer (2005) 1.31
Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med (2011) 1.31
Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience. Ann Surg (2006) 1.28
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer (2004) 1.27
Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer (2008) 1.25
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer (2003) 1.25
Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol (2009) 1.24
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol (2009) 1.24
Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer (2009) 1.23
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist (2011) 1.22
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer (2006) 1.21
Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer (2010) 1.21
A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis (2009) 1.20
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol (2009) 1.20
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer (2007) 1.19
Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res (2013) 1.18
Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. World J Surg (2008) 1.18
Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol (2010) 1.17
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer (2004) 1.17
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res (2014) 1.17
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorectal Dis (2005) 1.17
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer (2009) 1.16
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer (2005) 1.16
Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer (2008) 1.16
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol (2010) 1.16
Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag (2005) 1.16
Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) (2013) 1.15
Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol (2011) 1.15
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer (2007) 1.15
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer (2006) 1.14
Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer (2009) 1.14
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer (2008) 1.13
The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol (2011) 1.13
Novel metals and metal complexes as platforms for cancer therapy. Curr Pharm Des (2010) 1.13
Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci (2008) 1.12
Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain (2011) 1.12
Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer (2003) 1.11
Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev (2013) 1.11
Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Mol Pain (2012) 1.11
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol (2010) 1.11
Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review. Int J Colorectal Dis (2008) 1.11
Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci (2011) 1.10
Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol (2010) 1.10
Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials (2012) 1.10
Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract (2009) 1.10
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res (2009) 1.08
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer (2007) 1.08
Oxaliplatin-induced neuropathy in colorectal cancer. J Oncol (2011) 1.07
Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol (2012) 1.07
Inferior vena cava resection with hepatectomy: challenging but justified. HPB (Oxford) (2011) 1.06
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. J Cancer Res Clin Oncol (2008) 1.06
Effect of general practitioners' advice against smoking. Br Med J (1979) 24.07
THE NATURE OF THE PERIPHERAL RESISTANCE IN ARTERIAL HYPERTENSION WITH SPECIAL REFERENCE TO THE VASOMOTOR SYSTEM. J Clin Invest (1936) 18.94
Intercapillary Lesions in the Glomeruli of the Kidney. Am J Pathol (1936) 12.50
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
A plethysmographic method for measuring systolic blood pressure in the intact rat. J Physiol (1938) 7.20
Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet (2001) 6.92
Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol (1991) 6.19
P-element-mediated enhancer detection: a versatile method to study development in Drosophila. Genes Dev (1989) 5.76
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol (2000) 5.20
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol (2011) 4.95
Benign and Malignant Hypertension and Nephrosclerosis: A Clinical and Pathological Study. Am J Pathol (1936) 4.43
Genetic evidence for the spread of agriculture in Europe by demic diffusion. Nature (1991) 4.34
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (1999) 4.04
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol (2002) 3.98
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
A cytogenetic study of 1000 spontaneous abortions. Ann Hum Genet (1980) 3.82
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet (2000) 3.79
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75
Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature (1984) 3.64
Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (1997) 3.61
Inflammatory Lesions in the Glomeruli in Pyelonephritis in Relation to Hypertension and Renal Insufficiency. Am J Pathol (1936) 3.52
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
New world views: preparing physicians in training for global health work. Fam Med (2000) 3.23
A JNK signal transduction pathway that mediates morphogenesis and an immune response in Drosophila. Genes Dev (1996) 3.21
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med (1992) 3.11
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol (1997) 3.08
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol (2000) 3.04
Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell (1988) 2.91
Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev (1999) 2.87
Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol (2003) 2.87
Plasma nicotine levels after smoking cigarettes with high, medium, and low nicotine yields. Br Med J (1975) 2.80
Structure of the CAP-DNA complex at 2.5 angstroms resolution: a complete picture of the protein-DNA interface. J Mol Biol (1996) 2.80
Comparison of effect on tobacco consumption and carbon monoxide absorption of changing to high and low nicotine cigarettes. Br Med J (1973) 2.65
RNA secondary structure prediction based on free energy and phylogenetic analysis. J Mol Biol (1999) 2.65
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology (1997) 2.61
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol (2010) 2.54
Gastric cancer: epidemiology, pathology and treatment. Ann Oncol (2003) 2.53
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother (1981) 2.48
Effect of nicotine chewing gum on smoking behaviour and as an aid to cigarette withdrawal. Br Med J (1976) 2.41
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol (2004) 2.39
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
A computer-derived protocol to aid in the diagnosis of emergency room patients with acute chest pain. N Engl J Med (1982) 2.28
Mobile coronary care and community mortality from myocardial infarction. Lancet (1985) 2.27
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer (1999) 2.24
Stimulation and suppression of PCR-mediated recombination. Nucleic Acids Res (1998) 2.17
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer (1997) 2.14
Rural and urban differences in stage at diagnosis of colorectal and lung cancers. Br J Cancer (2001) 2.12
Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther (1995) 2.11
A microtest for the quantitation of rabies virus neutralizing antibodies. J Biol Stand (1979) 2.10
The treatment and prevention of obesity: a systematic review of the literature. Int J Obes Relat Metab Disord (1997) 2.10
Improving the detection rate of early gastric cancer requires more than open access gastroscopy: a five year study. Gut (1997) 2.09
Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol (2003) 2.07
On the scale of global demographic convergence, 1950-2000. Popul Dev Rev (2001) 2.07
Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J (2002) 2.06
alpha-DNA II. Synthesis of unnatural alpha-anomeric oligodeoxyribonucleotides containing the four usual bases and study of their substrate activities for nucleases. Nucleic Acids Res (1987) 2.06
Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol (1998) 2.05
Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem (1994) 2.04
Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol (2012) 2.04
HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene (2007) 2.00
Rural factors and survival from cancer: analysis of Scottish cancer registrations. Br J Cancer (2000) 1.97
Antibodies to proteus in rheumatoid arthritis. Lancet (1985) 1.96
Therapeutic Trial of Methionine in Infective Hepatitis. Br Med J (1945) 1.95
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol (2000) 1.92
A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics. Nature (1987) 1.91
Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol (2000) 1.91
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer (2011) 1.90
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.87
Acute chest pain in the emergency room. Identification and examination of low-risk patients. Arch Intern Med (1985) 1.86
The rat lipolytic beta-adrenoceptor: studies using novel beta-adrenoceptor agonists. Eur J Pharmacol (1984) 1.85
UV-Stimulated K Efflux from Rose Cells: Counterion and Inhibitor Studies. Plant Physiol (1982) 1.85
Comparison of increases in carboxyhaemoglobin after smoking "extra-mild" and "non-mild" cigarettes. Lancet (1973) 1.84
Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. Eur J Cancer (1997) 1.84
Perturbation of Chara Plasmalemma Transport Function by 2[4(2',4'-Dichlorophenoxy)phenoxy]propionic Acid. Plant Physiol (1984) 1.83
alpha-DNA. I. Synthesis, characterization by high field 1H-NMR, and base-pairing properties of the unnatural hexadeoxyribonucleotide alpha-[d(CpCpTpTpCpC)] with its complement beta-[d(GpGpApApGpG)]. Nucleic Acids Res (1986) 1.83
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol (2013) 1.82
Variability of the lytic susceptibility of Neisseria gonorrhoeae to human sera. J Immunol (1977) 1.81
Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas. Br J Cancer (2004) 1.80
Idiopathic granulomatous mastitis. A report of three cases and review of the literature. Arch Pathol Lab Med (1994) 1.79
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet (2002) 1.77
Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism (1987) 1.76
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol (1988) 1.74
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.73
Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer (1999) 1.72
Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer (2005) 1.71
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Characterization of the humoral immune response to Klebsiella species in inflammatory bowel disease and ankylosing spondylitis. Br J Rheumatol (1998) 1.69